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The cancer-risk-associated rs6983267 single nucleotide polymorphism (SNP) and the accompanying long noncoding RNA
CCAT2 in the highly amplified 8q24.21 region have been implicated in cancer predisposition, although causality has not
been established. Here, using allele-specific CCAT2 transgenic mice, we demonstrate that CCAT2 overexpression leads to spon-
taneous myeloid malignancies. We further identified that CCAT2 is overexpressed in bone marrow and peripheral blood of
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myelodysplastic/myeloproliferative neoplasms (MDS/MPN) patients. CCAT2 induces global deregulation of gene expression
by down-regulating EZH2 in vitro and in vivo in an allele-specific manner. We also identified a novel non-APOBEC, non-
ADAR, RNA editing at the SNP locus in MDS/MPN patients and CCAT2-transgenic mice. The RNA transcribed from the
SNP locus in malignant hematopoietic cells have different allelic composition from the corresponding genomic DNA, a phe-
nomenon rarely observed in normal cells. Our findings provide fundamental insights into the functional role of rs6983267
SNP and CCAT2 in myeloid malignancies.
[Supplemental material is available for this article.]
The cancer genome shows a remarkable degree of variation, as
revealed by the pervasive prevalence of copy number variations,
amplifications, inversions, rearrangements, and single nucleotide
polymorphisms (SNPs) (Stratton et al. 2009). Most SNPs of interest
are found in the noncoding regions (Freedman et al. 2011),
and because three-quarters of the human genome is transcribed
(Djebali et al. 2012), these SNPs could be sites of active transcrip-
tion of noncoding RNAs. The rs6983267(G/T) SNP in the
8q24.21 region is one such actively transcribed SNP that confers
an increased risk of colon, prostate, breast, and bladder cancers
(Haiman et al. 2007; Tomlinson et al. 2007; Zanke et al. 2007;
Ghoussaini et al. 2008).
Notably, the long noncoding RNA (lncRNA) Colon Cancer
Associated Transcript 2 (CCAT2) maps to this SNP and is tran-
scribed into 1.7-kb RNAs containing either the G (CCAT2-G) or
T (CCAT2-T) nucleotide at base pair 662 (Ling et al. 2013).
Variation in this single nucleotide results in an altered secondary
structure of the RNA at the SNP locus, accounting for the distinct
functional roles of the two RNAs. In colon cancer, CCAT2 alleles
can bind the two subunits of the Cleavage Factor I (CFIm) complex
with distinct affinities, thus regulating the alternative splicing of
glutaminase (GLS) and consequently reprogramming glutamine
metabolism (Redis et al. 2016). CCAT2 transcript is overexpressed
in microsatellite-stable (MSS) colon cancer, breast cancer, gastric
cancer, esophageal squamous cell carcinoma and non-small cell
lung adenocarcinomas (Ling et al. 2013; Redis et al. 2013; Qiu
et al. 2014; Cai et al. 2015; Wang et al. 2015a,b; Zhang et al.
2015) and was shown to induce chromosomal instability and
metastases in colon cancer by increasing MYC expression (Ling
et al. 2013). Although these studies support an oncogenic role
of rs6983267 SNP and CCAT2, a deeper investigation is warranted
to conclusively determine whether CCAT2 plays a causal role in
vivo in tumor initiation and if the G/T alleles have functional
consequences on the CCAT2-induced phenotype. In this study,
we undertook a comprehensive approach using two genetically en-
gineered in vivo models to determine (a) the tissue/organ that is
most sensitive to CCAT2 overexpression, (b) if CCAT2 overexpres-
sion alone is enough to induce spontaneous tumorigenesis in vivo,
and finally, (c) if the G/T SNP variation contributes to the function
of CCAT2.
Results
CCAT2 mice develop spontaneous myeloid malignancies
In order to study the role of CCAT2 and its specific alleles in the
regulation of cellular processes, we generated two transgenic
mouse models overexpressing allele-specific CCAT2 lncRNA. A
transcript of 1.7-kb human CCAT2 cDNA (CCAT2-G or CCAT2-T)
was expressed under the CAG promoter in C57BL/6N background
(Fig. 1A). Real-time qPCR (RT-qPCR), end-point PCR, and in situ
hybridization (ISH) confirmed overexpression of human CCAT2
in these mice (using human-specific primers and probes)
(Supplemental Fig. S1; Supplemental Table S1A). The∼1.7-kb tran-
script has ∼82% homology between human and mice. As a result,
theCCAT2 primers used to detect the∼1.7-kb transcript could also
potentially detect minimal basal murine CCAT2 transcription.
However, the CCAT2 primers used in the following experiments
detect a shorter transcript surrounding the SNP region that is
human specific. The CCAT2 overexpression level mimicked the
clinically relevantCCAT2 expression reported in severalmalignan-
cies (Ling et al. 2013; Redis et al. 2013; Qiu et al. 2014; Cai et al.
2015; Wang et al. 2015a,b; Zhang et al. 2015).
Within 7–9 mo of age, CCAT2-G mice (n = 20 from three dif-
ferent founders) and CCAT2-T mice (n = 20 from two different
founders) showed clinical signs of an aberrant hematological phe-
notype compared to age- and sex-matchedWT littermates (n = 20).
These mice exhibited massive leukopenia (reduction in white
blood cells or WBCs) and lymphocytopenia (decreased number
of lymphocytes) (Fig. 1B). Mild anemia (reduction in red blood
cells or RBCs) was also displayed in 47% of mice, and 54% showed
thrombocytosis (increase in platelets) (Fig. 1B; Supplemental Fig.
S2A).Moreover,CCAT2-G andCCAT2-Tmice showed a significant
increase in the number of large unstained cells (LUCs), which are
large atypical lymphocytes or blast cells, in their peripheral blood
(PB) (Supplemental Fig. S2B). Consistent with complete blood
counts, morphological analysis of CCAT2-G and CCAT2-T PB
smears (n = 10 for each) by Hema III staining revealed the presence
of several aberrant circulating blood cells, including polychromat-
ic RBCs,Howell-Jolly bodies, hypersegmentedneutrophils, pseudo
Pelger Huet cells, and macrothrombocytes (Fig. 1C). Bone marrow
(BM) aspirates from CCAT2-G and CCAT2-Tmice (n = 10 for each)
also exhibited consistent multilineage proliferative and dysplastic
changes (Fig. 1D). Hematoxylin and eosin (H&E) staining of
CCAT2-G and CCAT2-T mice BM sections (n = 15 for each allele)
showed significantly increased BM cellularity in one or multiple
cell lineages in comparison with WT mice (n = 15) (Fig. 1E;
Supplemental Fig. S2C). Gross examination and histological diag-
nosis confirmed marked extramedullary hematopoiesis (EMH) in
the spleen and liver of CCAT2 mice (P < 0.01), causing splenome-
galy and hepatomegaly (Supplemental Fig. S2D,E). These mice
also showed reduced iron deposition in their BM (Supplemental
Fig. S2F). Periodic Acid-Schiff (PAS), myeloperoxidase (MPO),
butyrate, reticulin, and trichrome stainings of the BM sections
did not show any significant aberrations or myelofibrosis in these
mice (Supplemental Fig. S2G–K). Collectively, because the features
exhibited by CCAT2-G and CCAT2-Tmice were characteristic hall-
marks of myelodysplastic/myeloproliferative neoplasms (MDS/
MPN) (Tefferi and Vardiman 2009; Bejar and Steensma 2014),
we concluded that these mice developed a phenotype resembling
the clinical manifestation of myeloid malignancies in humans
(Fig. 1F). The incidence of MDS/MPN was similar in both
CCAT2-G and CCAT2-Tmice, implying that both alleles are equal-
ly important and single-handedly sufficient in the development
of MDS/MPN (Fig. 1F; Supplemental Fig. S2L), and CCAT2 overex-
pression is the primary driver in MDS/MPN initiation.
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Figure 1. CCAT2mice display bonemarrow insufficiency with clinical features ofmyeloidmalignancies. (A) Schematic of CCAT2-plasmid cassette inserted
into the mouse genome using pronuclear injection. A cartoon depicting the allele-specific secondary structure of 1.7-kb CCAT2 transcripts, which differ
mostly at the ∼500 bp region surrounding the rs6983267(G/T) SNP, is shown at the bottom of panel A. (B) Peripheral blood counts of WT, CCAT2-G,
and CCAT2-Tmice. (C) Representative images of aberrant circulating peripheral blood cells in CCAT2-G and CCAT2-Tmice. Arrows indicate the aberrations
described. Images in the inset are 40×magnified aberrant cells. (D) Representative images of Hema III-stained aberrant cells present in bonemarrow smears
of CCAT2-G and CCAT2-T mice. Arrows and arrowheads indicate the aberrations described. Images in the inset are 40× magnified aberrant cells. (E)
Histologic sections of bone marrow (from femur) with H&E staining; 40× magnified. Normal bone marrow from WT mice (i) in comparison with myeloid
hyperplasic (ii), erythroid hyperplasic (iii), and megakaryocytic hyperplasic (iv) bone marrow from CCAT2-G and CCAT2-Tmice. (F) The incidence of mye-
lodysplastic and myeloproliferative clinicopathological characteristics in CCAT2-G and CCAT2-T mice are shown. Data are represented as median values ±
95% confidence interval. (∗) P < 0.05; (∗∗) P < 0.01; (∗∗∗) P < 0.001; (∗∗∗∗) P < 0.0001.
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CCAT2 induces genomic instability in vivo
BecauseCCAT2 induces genomic instability and aneuploidy inmi-
crosatellite-stable colon cancer (Ling et al. 2013) and BM cells of
MDS/MPN patients are often genomically unstable, we evaluated
metaphase spreads from BM cells of 8- to 9-mo-old WT (n = 4)
and CCAT2-G and CCAT2-T (n = 6 each) mice for abnormal
karyotypes. The BM cells of CCAT2-G and CCAT2-T mice had
significantly higher frequency of structural cytogenetic aberra-
tions, especially chromosomal breaks, than those of the WT
mice (P < 0.05) (Supplemental Fig. S3A). These results showed
that widespread global genomic instability and consequent dysre-
gulation of hematopoiesis by CCAT2 might be a key event in
the initiation of MDS/MPN. Ki67 proliferation analysis demon-
strated that BM of CCAT2-G and CCAT2-Tmice presented signifi-
cantly more Ki67-positive cells than WT BM (n = 3 for each
group, P < 0.001) (Supplemental Fig. S3B). Similarly, the rate of
apoptosis was also significantly higher in these BM (n = 3 for
each group, P < 0.01) (Supplemental Fig. S3C). These data suggest-
ed a prominent dysregulation of hematopoietic cell maturation
andmaintenance in CCAT2mice, whichmight play an important
role in BM failure.
CCAT2 mice display hematopoietic stem cell exhaustion
In order to characterize the hematopoietic stem cell (HSC) popula-
tion in these mice, we performed flow cytometry on BM cells
from CCAT2-G, CCAT2-T, and WT mice (n = 8 for each group).
The MDS-like and MPN-like mice had significantly different HSC
populations in their BM. The proportion of LSK (Lin−Sca1+cKit+)
cells was significantly lower in MDS-like CCAT2 mice than in
MPN-likeCCAT2 andWTmice (Fig. 2A). Additionally, the percent-
ages of long-term HSCs (LT-HSCs) and short-term HSCs (ST-HSCs)
were also significantly lower only in MDS-like CCAT2 mice (Fig.
2A). Further analysis of myeloid-committed progenitor cells re-
vealed a significant expansion of the granulocytic–monocytic pro-
genitor (GMP) cell compartment, whereas the megakaryocytic–
erythroid progenitor (MEP) population was reduced (P < 0.05)
(Fig. 2B). In vitro HSC colony formation assay demonstrated a sig-
nificant decrease in colony-forming capabilities ofHSCs fromboth
MDS-like and MPN-like CCAT2 mice (P < 0.01 and P < 0.001, re-
spectively, in Fig. 2C, left). Serial replating assay of HSCs from
MDS-like and MPN-like CCAT2 mice revealed a remarkable
decrease in their repopulating efficiency in vitro compared to
WT HSCs (P < 0.001) (Fig. 2C, right). These data confirmed that
the self-renewal and differentiation efficiency of HSCs was signifi-
cantly diminished in CCAT2 mice.
Among lineage-positive cells, the percentage of early-stage
(pro–pre) and immature B cells was significantly reduced in
MDS-like CCAT2 mice compared to WT and MPN-like mice (Fig.
2D). This correlated with HSC exhaustion and lower peripheral
WBC levels in MDS-like CCAT2 mice. Conversely, MPN-like
CCAT2 mice displayed a significant increase in early-stage and
immature B cells, suggesting a block in B-cell differentiation (Fig.
2D). Further analysis of early-stage (pro–pre) and immature B
cells revealed an increase in the expression of Il-7 receptor alpha
(Il-7rα) and CD79b markers that play an important role in B-cell
development (Fig. 2E). Dysregulation of these genes might help
explain the B-cell aberrations exhibited by CCAT2 mice.
Additionally, we noted a distinct infiltration of activated CD8+ T
cells in the BM of these mice (Fig. 2F). However, no distinct dysre-
gulation of developmental markers (including CD44, CD62l,
CD25, CD49b, CD223, CD357, and Folate Receptor 4) was identi-
fied in immature T cells. Collectively, the flow cytometry data
highlighted two distinct phenotypes (MDS-like and MPN-like) in-
duced in CCAT2mice, suggesting that CCAT2 plays an important
role in regulating the HSC pool.
CCAT2-induced myeloid malignancies show age-dependent
progression
The blood counts, BM histology, and cytology analysis of CCAT2-
G and CCAT2-Tmice at different ages (young: 4–6 mo; old: 15–18
mo) detected an increased incidence of MPN with age. Early signs
of mild hyperplasia were noted in the BM of young mice, which
corroborated with mild cytopenias observed in their PB (n = 8
for each group) (Supplemental Fig. S4A,B). Conversely, PB counts,
H&E staining, and histology showed widespread hyperplasia,
cytopenia, and splenic EMH in old mice (n = 8 for each group)
(Supplemental Fig. S4C,D). CyTOF mass cytometry on BM cells
of young mice (n = 3 for each group) showed mild expansion of
myeloid lineage cells and reduction of erythroid cells in CCAT2
mice compared to age-matched WT mice (Supplemental Fig.
S4E). In addition, a threefold increase in CD34+ blast cells was
also observed in the BM of these mice (Supplemental Fig. S4F),
suggesting that CCAT2 induced significant HSC dysfunction at
an early age in thesemice. Similar incidence of myeloid expansion
and blast cells was also observed in old CCAT2 mice compared to
age-matchedWTmice (n = 3 for each group, P < 0.05). A significant
age-dependent increase in immature/progenitor cells was observed
in the BM of CCAT2 mice compared to WT mice (Supplemental
Fig. S4G), indicating inhibition of HSC maturation. In addition,
we observed a gradual progression to MPN-like phenotype with
age, with 95% of old mice displaying MPN-like symptoms
(Supplemental Fig. S4H). However, no difference was observed
between the overall survival of WT, CCAT2-G, and CCAT2-T
mice (n = 65 until the age of 24 mo, P = 0.424). Taken together,
these results indicated that CCAT2 induced gradual HSC exhaus-
tion and dysfunction, resulting in an age-dependent progression
to MPN, but no progression to acute leukemia, characteristics
consistent with low-risk MDS/MPN in humans.
CCAT2-induced myeloid malignancies are transplantable
To test if the CCAT2-induced myeloid malignancies were caused
by a primary defect in the BM cells or by a dysregulated microen-
vironment, we performed transplantation experiments. Lethally
irradiated 3-mo-old CD45.1 WT mice (congenic to CD45.2
C57Bl6mice used to generateCCAT2 transgenicmice) were recon-
stituted with BM cells from 9-mo-oldCCAT2-G andCCAT2-Tmice
with MDS or MPN (CCAT2-to-WT transplantation) or WT mice
(WT-to-WT transplantation) (n = 10 for each group) (Fig. 3A).
TheCD45.1 recipientmice showed full reconstitution of the donor
CD45.2 BM cells 1 mo post-transplantation (Fig. 3B). Within 3mo
of transplantation, theCCAT2-to-WT groupmice developedMDS/
MPN features. PB showed progressive leukopenia, lymphocytope-
nia, and anemia (Fig. 3C). Necropsies demonstrated splenomegaly
and hepatomegaly in the CCAT2-to-WT group, but not in the
WT-to-WT group (Fig. 3D).CCAT2-to-WTgroup BMwas dysplastic
and hyperproliferative for one or multiple cell lineages in compar-
ison with WT-to-WT mice (Fig. 3E). Additionally, BM aspirates
from CCAT2-to-WT group exhibited consistent multilineage
dysplastic changes (n = 5 mice for each group) (Fig. 3F). Only
one of the WT-to-WT controls showed signs of early-stage
MDS. Finally, flow cytometry analysis confirmed exhaustion
of HSCs in CCAT2-to-WT mice compared to WT-to-WT mice
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(Fig. 3G). Collectively, 16/20 (80%)CCAT2-to-WTmice developed
MDS, whereas 3/20 (15%) developed MPN (Fig. 3H). These find-
ings confirmed that the CCAT2-to-WT group mice presented
dysplastic changes identical to CCAT2-G and CCAT2-T mice
and indicated that CCAT2 overexpressing myelodysplastic BM
cells are sufficient to initiate MDS/MPN in radiation conditioned
WT mice.
CCAT2 is overexpressed in MDS patients
To assess the relevance of these findings in humans, we examined
CCAT2 expression in CD34+ BM cells (MDACC cohort, n = 86) and
PB mononuclear cells (ROM cohort, n = 54) of MDS patients
and age- and sex-matched healthy individuals (n = 8 CD34+ BM
samples and n = 55 PB mononuclear cell samples). We identified
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Figure 2. Bone marrow cells of CCAT2 mice display exhaustion of hematopoietic stem cells. (A) Flow cytometry analysis of hematopoietic stem cells in
MDS- and MPN-like CCAT2 mice compared to WT mice. Cells analyzed include LSK (Lin−Sca1+cKit+) cells; long-term HSCs (LT-HSCs, defined by
Lin−cKit+Sca1+CD34loCD135lo population); and short-term HSCs (ST-HSCs, defined by Lin−cKit+Sca1+CD34hiCD135lo population). (B) Flow cytometric
analysis of hematopoietic progenitor cells in MDS- andMPN-like CCAT2mice compared to WTmice. Cells analyzed include commonmyeloid progenitors
(CMPs, Lin−cKit+Sca1−/loCD34+FcγRlo population); granulocyte–macrophage progenitors (GMPs, Lin−cKit+Sca1−CD34+FcγR+ population) and megakar-
yocyte–erythroid progenitors (MEPs, Lin−cKit+Sca1−CD34−FcγR− population). (C) In vitro colony formation assay (left) and in vitro serial replating analysis
(right) using bone marrow cells of WT, MDS-, andMPN-like CCAT2mice. Data are average of three independent experiments done in triplicates. (D,E) Flow
cytometry analysis of B cells in different developmental phases (D) and expression of developmental markers Il-7rα and CD79b in pro–pre B cells (E) of
CCAT2 mice compared to WT mice. (F ) Flow cytometric analysis of T cells in different developmental phases in CCAT2-G and CCAT2-T mice compared
to WT mice. Data are represented as mean values ±SEM. (∗) P < 0.05; (∗∗) P < 0.01; (∗∗∗) P < 0.001.
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Figure 3. CCAT2-induced myeloid malignancies are transplantable. (A) Schematic of the transplantation experiments. (B) Flow cytometric analysis to
identify proportion of CD45.2+ cells in peripheral blood and bone marrow of CCAT2-to-WT and WT-to-WT groups. (C) Peripheral blood counts
(CD45.2+) of WT-to-WT and CCAT2-to-WT groups mice. Data are represented as mean values ± SEM. (D) Spleen-to-body-weight ratio (left) and liver-to-
body-weight ratio (right) of WT-to-WT and CCAT2-to-WT groups (upper). Representative images of spleen and liver from CCAT2-to-WT mice are shown
below. (E) Histologic sections of bone marrow (from femur) with H&E staining of WT-to-WT and CCAT2-to-WT groups; 40× magnified. (F )
Representative images of Hema III-stained aberrant cells present in bone marrow smears of CCAT2-to-WT mice. (G) Flow cytometric analysis of hemato-
poietic stem cells in CCAT2-to-WT mice compared to WT-to-WT mice. Cells analyzed include LSK (Lin-Sca1+cKit+) cells. (H) Incidence of myelodysplastic
and myeloproliferative clinicopathological characteristics in CCAT2-to-WT and WT-to-WT mice are shown. Data are represented as median values ± 95%
confidence interval. (∗) P < 0.05; (∗∗∗) P < 0.001.
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significantly higher CCAT2 expression in MDS patients (P < 0.05)
(Fig. 4A). CCAT2 expression was also significantly higher in pa-
tients with stable MDS compared to patients that presented with
MDS at diagnosis but eventually succumbed to AML (P < 0.05)
(Fig. 4B). Further, CCAT2 expression in patients with Trisomy 8,
who have an extra copy of Chromosome 8 (Paulsson and
Johansson 2007), was similar to CCAT2 expression in patients
with other genetic abnormalities (P < 0.05) (Fig. 4C), implying
that an extra Chromosome 8 is not a major factor promoting
CCAT2 overexpression in MDS patients. CCAT2 expression
levels were also significantly higher in the PB mononuclear cells
(MNCs) of MDS patients when compared to normal healthy indi-
viduals (ROM cohort, P < 0.05) (Fig. 4D). In addition, high CCAT2
expression levels correlated with low risk (P < 0.01) (Fig. 4E) and
low percentage of BM and PB blasts in MDS patients (P < 0.05)
(Fig. 4F). Collectively, MDS patient results validated our transgenic
mice data thatCCAT2 is important inMDS, and further studywith
more patient data sets will be required to understand the relation-
ship between CCAT2 expression and MDS progression.
CCAT2 exhibits startling DNA-to-RNA allelic imbalances
at the SNP locus in MDS
Because rs6983267 SNP has been linked to cancer risk, we next
sought to determine the correlation between CCAT2 overexpres-
sion and allelic composition at the SNP locus in MDS patients.
For this purpose, we performed two independent assays, Sanger se-
quencing and allele-specific restriction enzyme digestion (using
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Figure 4. CCAT2 is overexpressed in MDS patients. (A,B) CCAT2 expression in CD34+ bone marrow cells of MDS patients and healthy individuals. (A)
Comparison between healthy individuals and MDS patients. (B) Comparison between MDS patients who progressed and those who did not progress
to secondary AML. (C) CCAT2 expression in CD34+ bonemarrow cells ofMDS patientswith Trisomy 8, other genetic abnormalities, and healthy individuals.
(D) CCAT2 expression in peripheral blood ofMDS patients and healthy individuals. (E) Correlation between CCAT2 expression inMDS patients and their risk
category (classified according to IPSS risk classification). (F) Correlation betweenCCAT2 expression and percent blasts in bonemarrow and peripheral blood
of MDS patients. Data are represented as median values ±95% confidence interval. (∗) P < 0.05.
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Tsp45I enzyme that cuts onlyCCAT2-T) (Supplemental Fig. S5A,B)
on PCR-amplified region surrounding the rs6983267 SNP (using
primers CCAT2_2F+2R in Supplemental Table S1A) in both geno-
mic DNA (gDNA) and cDNA fromCD34+ BM cells and PBMNCs of
these patients. We identified a normal distribution of allelic fre-
quencies in the gDNA of this population (GG = 0.30, GT = 0.55,
and TT = 0.15, n = 161), whichmatches the natural allelic distribu-
tion of this SNP in normal population (NCBI SNP database). We
found that the gDNA and cDNA sequences from the same patient
were not an exact match at the SNP locus (Fig. 5A,i–ii). Although
the gDNA of only 52% patients in the MDACC cohort (CD34+
BM cells) was heterozygous at the SNP locus, 74% of these patients
expressed both CCAT2 alleles at the RNA level (CCAT2-GT, P =
0.003) (Fig. 5A,i; Supplemental Fig. S5C). We also observed this
phenomenon in the PB MNCs of MDS patients (ROM cohort)
(Fig. 5A,ii; Supplemental Fig. S5D). In this cohort, cDNA of 87%
patients was heterozygous at the SNP locus compared to only
60% patients that were heterozygous at the gDNA (P = 0.002)
(Fig. 5A,ii). These discrepancies between DNA and RNA were
only observed at this specific locus in CCAT2. In addition, we nev-
er identified nonphysiological alleles (C or A) at this locus.We con-
cluded that this phenomenon of DNA-to-RNA allelic imbalances
represented a novel non-APOBEC, non-ADAR, SNP rs6983267-
specific RNA editing event. Only samples confirmed by both
Sanger sequencing and restriction digestion were labeled as
rs6983267-specific RNA editing (RE) positive (RE+) (Supplemental
Fig. S5A). In addition, we used various types of reverse transcriptas-
es and polymerases to confirm this was not a technique-intro-
duced artifact (Methods).
Next, to determine if rs6983267-RE was disease specific, we
sequenced the gDNA and cDNA at the SNP locus in BM (n = 5)
and PB (n = 57) of age- and sex-matched healthy individuals. No
significant differences between gDNA and cDNA were detected
in these individuals (Fig. 5A,iii–iv). The rate of rs6983267-RE
incidence was much higher in MDS/MPN patients compared to
healthy individuals (23.6% versus 3.2%, respectively) (Fig. 5B),
suggesting that CCAT2-associated rs6983267-RE was significantly
enriched in MDS/MPN patients. We then analyzed paired BM and
PB samples from sixMDSpatients, and detected that two (33%) pa-
tients had the exact same editing in their BM and PB, suggesting
that rs6983267-RE could be potentially induced in the HSC
compartment first. Figure 5C shows the Sanger sequencing data
for two RE+ MDS/MPN patients. rs6983267-RE predominantly
induced conversion of homozygous DNA to heterozygous RNA
(P < 0.0001) (Fig. 5D). Further, rs6983267-RE+ patient samples
have significantly higher CCAT2 expression levels compared to
rs6983267-RE-negative patients (RE−, P = 0.024) (Fig. 5E). Because
the functional output of rs6983267-RE is expression of CCAT2-
GT, we compared patients that expressed CCAT2-GG and CCAT2-
TT to patients that expressed CCAT2-GT. CCAT2-GT patients had
higher CCAT2 levels in their BM and PB compared to CCAT2-GG
or CCAT2-TT patients (P < 0.05) (Fig. 5F). As expected, CCAT2-GT
also correlated with low-risk MDS compared to patients with
CCAT2-GG or CCAT2-TT (P = 0.028) (Fig. 5G). Figure 5H describes
the rs6983267-REprofile forall patients evaluated inthis study, along
with their clinical characteristics. Collectively, our data identified a
novel form of RNAmodification prevalent inMDS/MPN patients.
CCAT2 induces rs6983267-RE in vivo
Based on our patient data, we believe CCAT2 expression was a pre-
requisite for rs6983267-RE; however, CCAT2 expression alone
might not be enough to induce this editing. To determine if
CCAT2 was important for rs6983267-RE occurrence, we analyzed
the gDNA and cDNA of CCAT2 transgenic mice. We reasoned
that if the human CCAT2 transcript played an active role in induc-
tion of rs6983267-RE, then the transgenic mice would also display
rs6983267-RE. Analysis of the gDNA and cDNA sequences from
BM and PB of CCAT2-G and CCAT2-Tmice using human-specific
CCAT2 primers revealed a similar incidence of rs6983267-RE
in these mice (P < 0.0001) (Fig. 5I; Supplemental Fig. S5E,F), and
34% of the mice were heterozygous for CCAT2 transcript, express-
ing both G- and T- nucleotides. We confirmed our sequencing and
restriction digestion data using digital droplet PCR (ddPCR) on two
rs6983267-RE− and one rs6983267-RE+mice samples with enough
DNA and RNA to be tested by all threemethods (Supplemental Fig.
S5G). This was remarkable considering that the genomic cDNA in-
serted into thesemice contained only a single nucleotide (either G
or T) (Supplemental Fig. S1C). Use of human-specificCCAT2 prim-
ers eliminated the possibility that endogenous mouse CCAT2
might be confounding the data. To understand the role of editing
in CCAT2-induced phenotype, we compared RE+ and RE− CCAT2-
mice. Phenotypic comparison between these mice revealed that
rs6983267-RE+ mice were more prone to have splenomegaly and
BM hypercellularity compared to rs6983267-RE− mice (P = 0.004
and 0.048, respectively) (Fig. 5J). Figure 5K shows the detailed
phenotypic comparison between rs6983267-RE+ and rs6983267-
RE− mice. Spontaneous occurrence of RNA editing in CCAT2
mice implied that human CCAT2 sequence played an important
role in the incidence of rs6983267-RE.
rs6983267-RE causes significant immune dysregulation
in CCAT2-induced myeloid malignancies
To study the global alterations induced by rs6983267-RE, we per-
formed a genome-wide expression profiling (Affymetrix microar-
ray) on BM cells of WT mice (n = 4), CCAT2-G and CCAT2-T
mice (RE− group, n = 8), and CCAT2-GT mice (RE+ group, n = 6).
We found significant expression variations in RE+ or RE− mice
compared to WT mice, as well as RE+ mice compared to RE− mice
(Fig. 6A). We identified Socs3, an inhibitor of JAK/STAT pathway
and Ighg, a critical immune regulator, to be significantly dysregu-
lated in both rs6983267-RE+ and rs6983267-RE− mice compared
to WT mice (Fig. 6B). Significant changes were observed in RE−
CCAT2-G versus RE− CCAT2-T mice (Fig. 6C), indicating that
both alleles might function via different mechanisms to initiate
myeloid malignancies. Genome-wide comparison of RE+ mice
with RE− and WT mice revealed 22 genes that were significantly
altered by rs6983267-RE (Fig. 6D). These included important
immune regulators and B-cell receptor signaling pathway genes
CD16, CD79a, CD79b, Igll1, and Ighg (Fig. 6D).
Pathway analysis revealed that although RE− mice displayed
genome-wide changes associated with diverse cellular processes
(Fig. 6E), RE+ mice displayed significant dysregulation of genes
involved primarily in immune regulation (Fig. 6F). We identified
a significant down-regulation of important immune-related genes
in these mice (Fig. 6G). This implied that although CCAT2-G and
CCAT2-T independently regulated a large cohort of genes, the pres-
ence of both RNAs in rs6983267-RE+ mice led to substantial im-
mune impairment in vivo (Fig. 6F,G). We identified pathways
involved in antigen presentation, autoimmunity, immunodeficien-
cy, B-cell receptor signaling, B-cell development, T cell differentia-
tion, CDC42 signaling, IL22 signaling, and IL4 signaling (Fig. 6H).
Several of these genes and pathways, such as immunodeficiency
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Figure 5. MDS patients display a novel non-APOBEC, non-ADAR, SNP-specific RNA editing at rs6983267 SNP. (A) Allelic imbalance between genomic
DNA and CCAT2 cDNA at the SNP locus in CD34+ bone marrow cells (MDACC cohort) (i) or peripheral blood mononuclear cells (ROM cohort) of MDS
patients (ii), and in CD34+ bone marrow cells (iii) or peripheral blood (iv) of healthy individuals. (B) Pie charts depicting the rate and types of
rs6983267-RE observed in CD34+ bone marrow cells or peripheral blood mononuclear cells of MDS patients compared to healthy individuals. (C )
Representative examples of two rs6983267-RE+ patients by Sanger sequencing of the genomic DNA and CCAT2 cDNA at the SNP locus. (D)
Correlation between incidence of rs6983267-RE according to the genotype of MDS/MPN patients. (E) Correlation between CCAT2 expression levels
and incidence of rs6983267-RE in MDS/MPN patients. (F) CCAT2 expression in patients that express CCAT2-GT compared to patients that express
CCAT2-GG or CCAT2-TT. (G) Correlation between patients that express CCAT2-GT, CCAT2-GG, or CCAT2-TT and their risk category (classified according
to IPSS risk classification). (H) CCAT2 expression levels, incidence of rs6983267-RE, and clinical features for each MDS/MPN patient analyzed are shown.
(I,J) Rate of rs6983267-RE occurrence in the bonemarrow cells of CCAT2mice. (K ) The incidence of rs6983267-RE andMDS/MPN clinicopathological char-
acteristics displayed by CCAT2 mice are shown. Data are represented as mean values ± SEM. (∗) P < 0.05.
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Figure 6. CCAT2 induces global gene expression dysregulation in vivo. (A) Scatter plots representing genes that were significantly up-regulated (in red)
and down-regulated (in blue) in bone marrow cells of rs6983267-RE+ versus WT mice, rs6983267-RE− versus WT mice, and rs6983267-RE+ versus
rs6983267-RE− mice (P≤ 0.05, fold change ≥1.5). (B) Venn diagram showing genes dysregulated in rs6983267-RE+ versus WT mice and rs6983267-
RE− versus WT mice. Expression level fold changes of commonly regulated genes are shown below. (C) Scatter plots representing genes that were signifi-
cantly up-regulated (in red) and down-regulated (in blue) in bone marrow cells of CCAT2-Gmice compared to CCAT2-Tmice. (D) Venn diagram showing
genes dysregulated in rs6983267-RE+ versus WT mice and rs6983267-RE+ versus rs6983267-RE− mice. Expression level fold changes of commonly regu-
lated genes are shown to the right. (E,F ) Pie diagrams depicting the top differentially regulated pathways, grouped according to their molecular function, in
bone marrow cells of rs6983267-RE− (E) or rs6983267-RE+ (F) mice as described. (G) Scatter plot of significantly aberrantly regulated immune genes in the
bone marrow cells of rs6983267-RE+ or rs6983267-RE− mice as described. Most important genes are listed. (H) Top canonical pathways altered in bone
marrow cells of rs6983267-RE+ mice compared to WT or rs6983267-RE−mice, grouped according to their molecular function as determined by Ingenuity
Pathway Analysis.
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signaling, B-cell receptor signaling, and IL4 signaling, were previ-
ously implicated as functionally altered in MDS, MPN, and
other myeloid malignancies (Pellagatti et al. 2010). In order to
confirm immune dysregulation by rs6983267-RE, we performed
nCounter PanCancer Immune Profiling Panel (NanoString
Technologies) analysis onhematopoietic stemandprogenitor cells
(HSPCs) fromWT (n = 4), RE+ (n = 5), andRE− (n = 3)mice.We iden-
tified significant dysregulationof important immunegenes only in
RE+ mice compared to WT and RE−mice (Supplemental Fig. S6A).
CD22,CD19 andH2-Ob (Histocompatibility 2,O region beta locus)
were overlapping immune genes that were dysregulated in both to-
talBMandenrichedHSPCs.Becauseweobserved immunedysfunc-
tion in complete BM as well as enriched HSPCs of rs6983267-RE+
mice, we concluded that immune dysregulation could potentially
be a function of RNA editing and not due to differences in the cel-
lular composition of the BM of these mice.
At the same time, commonalities and differences in gene ex-
pression patterns were also apparent between the MDS-like and
MPN-like CCAT2 mice (Supplemental Fig. S6B,C). We observed a
significant increase in the number of dysregulated genes and
consequent enrichment of deregulated pathways in MPN-like
CCAT2 mice, which possibly reflected increased disease severity.
MPN-like mice showed a significant enrichment of immune-relat-
ed genes and associated pathways (Supplemental Fig. S6D), sug-
gesting that immune deregulation is an important phenomenon
in CCAT2-induced myeloid malignancies. We also analyzed the
microarray data to identify dysregulated processes that might
provide a hint for the rs6983267-RE mechanism. We identified
several genes that play an important role in DNA–RNA binding,
nucleotide biosynthesis, and transcription to be deregulated in
rs6983267-RE+mice (Supplemental Fig. S6E). These data suggested
that the altered function of the transcriptionmachinery byCCAT2
might be a potential mechanism of rs6983267-RE that needs to be
further evaluated.
CCAT2 regulates EZH2 in vitro and in vivo
We further identified Ezh2 to be down-regulated in the BM cells of
both CCAT2-G and CCAT2-T mice compared to WT littermates
(Fig. 7A). A corresponding decrease in global H3K27me3 levels,
an epigenetic marker for transcriptional silencing by polycomb re-
pressive complex 2 (PRC2) was observed (Fig. 7A). Clinically, 10%
of MDS patients show loss-of-function mutations in EZH2, and
these mutations are associated with shorter survival (Ernst et al.
2010). EZH2 loss has also been reported to induce MDS/MPN in
vivo, but mitigate its transformation to leukemia (Tanaka et al.
2012; Muto et al. 2013; Sashida et al. 2014; Mochizuki-Kashio
et al. 2015). Compromised Ezh2 function in our model might po-
tentially explainwhyCCAT2-G andCCAT2-Tmice do not progress
to AML, even after 24 mo. Based on this, we decided to further
study the regulation of EZH2 by CCAT2.
We confirmed EZH2 down-regulation in human HEK293
and mouse MEF cell lines (Supplemental Fig. S7A). Ezh2 and
H3K27me3 levels are reduced in hematopoietic stem and progen-
itor cells (HSPCs) as well as lineage-positive BM cells of CCAT2
mice (Fig. 7B). Gene enrichment analysis of microarray data iden-
tified a positive enrichment of EZH2-regulated targets defined in
human cancers (obtained from the Molecular Signature database
[MSigDB]) in the BM cells of CCAT2-G and CCAT2-Tmice (hyper-
geometric probability distribution analysis, common CCAT2:
EZH2 targets = 25, representation factor: 2.0, P < 3.471 × 10−4).
Several EZH2 downstream targets were identified to be dysregu-
lated in these mice (Supplemental Fig. S8B). Because Ezh2 mRNA
levels were not altered in BM cells of CCAT2 mice (Supplemental
Fig. S7C), we sought to determine if CCAT2 altered EZH2 levels
post-transcriptionally. EZH2 has been reported to interact with
CCAT2 as well as other lncRNAs (Tsai et al. 2010; Kotake et al.
2011; Hirata et al. 2015; Wang et al. 2016; Deng et al. 2017); we
thus studied CCAT2:EZH2 direct interaction. Indeed, using RNA
pulldown analysis, we discovered that EZH2 binds to both
CCAT2-G and CCAT2-T in HEK293 cells (stronger interaction
with CCAT2-T) (Fig. 7C). Artificial in vitro mutation of the SNP
to A or C nucleotides (that never occur in the human population)
further confirmed the specificity of EZH2:CCAT2 interaction by
RNA pulldown analysis (Fig. 7D). RNA immunoprecipitation
(RIP) analysis on the BM cells from WT, CCAT2-G, and CCAT2-T
mice (n = 3) detected a significant enrichment of both CCAT2-G
and CCAT2-T transcripts by real-time qPCR, validating the direct
interaction of EZH2 with CCAT2 (Fig. 7E). RIP analysis after
overexpressing CCAT2 and EZH2 showed a significant increase
in the strength of the EZH2:CCAT2 interaction (Supplemental
Fig. S7D). In addition, we confirmed EZH2:CCAT2 interaction in
the SET2 MPN cell line, which is a more relevant disease model
(Supplemental Fig. S7E).
To understand how CCAT2 regulated EZH2 expression, we
performed cycloheximide chase assay for protein stability on
HEK293 cells overexpressing CCAT2-G, CCAT2-T, or Empty
(pcDNA3 control) vectors. After 10 h of cycloheximide treatment,
EZH2 levels were reduced to 70% and 62% compared to the 0-h
time point in the CCAT2-G and CCAT2-T clones, respectively,
but no significant reduction was noted in the Empty clones (P <
0.05) (Fig. 7F). We detected a strong inverse correlation between
CCAT2 expression and EZH2 protein levels in CD34+ BM of
MDS patients (MDACC cohort, n = 24, r =−0.435, P = 0.033)
(Supplemental Fig. S7F). Finally, we compared EZH2 protein levels
in BM cells of rs6983267-RE+ and rs6983267-RE− CCAT2 mice.
rs6983267-RE+ mice exhibited markedly lower levels of Ezh2
protein as well as mRNA in their BM cells (Supplemental Fig.
S7G). Collectively, these data indicated that CCAT2 regulated the
expression of EZH2, and the simultaneous presence of both
CCAT2 RNA alleles by rs6983267-RE achieved a stronger down-
regulation of EZH2, thus providing a combined advantage to
the oncogenic function of CCAT2. Taken together, our data indi-
cate that CCAT2 overexpression leads to genomic instability and
rs6983267-RE, which in turn results in a genome-wide gene ex-
pression dysregulation, resulting in compromised EZH2 function
and impairment of immune processes, and thus inducing MDS/
MPN (Fig. 7G).
Discussion
One of the greatest challenges in the post-genome-wide associa-
tion studies (GWAS) era is to understand the functional and bio-
logical significance of SNPs and derive insights that can be
translated to clinical benefits (Freedman et al. 2011). Through an
integrated approach, we successfully deciphered the clinical im-
portance of cancer-risk associated rs6983267 and the accompany-
ing CCAT2 lncRNA. Constitutive overexpression of allele-specific
CCAT2 altered the global gene expression landscape in the
hematopoietic cells, which ultimately initiated de novo myeloid
malignancies, indicating that both alleles are important. We also
identified a novel SNP-associated RNA mutation that is highly
prevalent in cancer cells: the rs6983267-RE. Via this phenomenon,
the aberrant malignant cells can potentially control the
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transcription of rs6983267 SNP locus (and potentially several oth-
er loci to be identified) and preferentially produce heterozygous
transcripts fromhomozygousDNA. This study reveals that actively
transcribed SNPs might have a more fundamental role in genetic
regulation than previously understood.
We propose that rs6983267-RE is a purposeful, systematic,
and precisely regulated event in human MDS/MPN.
rs6983267-RE is purposeful: We found this to be significantly
more frequent in premalignant MDS/MPN syndromes compared
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Figure 7. CCAT2 regulates EZH2 in vitro and in vivo. (A,B) Western blot analysis on complete BM cells from CCAT2-G, CCAT2-T, and WT mice (A), and
hematopoietic stem and progenitor cells (HSPCs) and lineage-positive cells from CCAT2-G, CCAT2-T, andWTmice (B). (C,D) Western blot analysis for EZH2
in cell lysates from GST-tagged allele-specific CCAT2-overexpressing HEK293 cells following RNA pulldown experiment. (C) TCF7L2 was used as a positive
control and B-Action as a negative control for CCAT2 interaction. (D) Pulldown analysis after overexpressing nonphysiological A and C alleles of the SNP. (E)
RT-qPCR for CCAT2 expression in BM cells of CCAT2-G, CCAT2-T, and WTmice following RNA Immuno-Precipitation by EZH2 antibody (right). HOTAIRwas
used as a positive control and U6 as a negative control for EZH2 interaction. All expression levels were normalized to input. End-point PCR for CCAT2 and
Western blot analysis showing efficiency of EZH2 RIP (left). (F ) Western blot analysis to detect EZH2 levels following treatment of CCAT2-overexpressing-
HEK293 cells with cycloheximide for 0, 2, 4, 6, 8, and 10 h. Upper panel shows quantification of three independentWestern blot experiments performed in
triplicates. (G) Schematic model of proposed mechanism of CCAT2-induced MDS/MPN phenotypes. Data are represented as mean values ±SEM. (∗) P <
0.05; (∗∗) P < 0.01.
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to healthy individuals, suggesting it might be an important mech-
anism adopted by aberrant cells, which gives rs6983267-RE a
cellular purpose. The importance of this event can be emphasized
by the fact that although only 54% of the MDS patients in our co-
horts were heterozygous for the SNP at the DNA level (similar to
the normal distribution of the SNP alleles in the healthy human
population), 78% of these patients actually expressed heterozy-
gous CCAT2 RNA. Additionally, the presence of rs6983267-RE at
the cancer-predisposing rs6983267 SNP, embedded in an onco-
genic lncRNA (CCAT2), and located within the most commonly
amplified 8q24 region, suggest rs6983267-RE could have impor-
tant biological consequences.
rs6983267-RE are systematic and regulated: If the rs6983267-RE
detected in MDS/MPN patients was random cellular noise, then
the nucleotide variations would be arbitrary; namely, the nonphy-
siological A and C alleles (that never occur in human population)
would also be identified. However, the fact that the variations al-
ways involved only the physiologically relevant G and T alleles
of the SNP in 100% of studied cases suggest that rs6983267-RE is
systematically regulated. This is further supported by the hu-
man–mouse conservation that we observed. We identified the RE
in MDS/MPN patients as well as in the CCAT2-induced MDS/
MPNmice (where the human CCAT2 cDNAwas inserted random-
ly in the mouse genome). This implied that the CCAT2 genomic
locus might act in cis to induce the rs6983267-RE and thus control
the transcription at its SNP site, further emphasizing that it is a
carefully regulated phenomenon.
Another important implication is the significant accumula-
tion of both CCAT2 alleles (heterozygosity at the SNP locus), im-
plying that both alleles are important in MDS/MPN initiation.
We previously reported the allele-specific functionality of CCAT2
in colon cancer. TheCCAT2Gand T alleles differentiallymodulate
cellularmetabolism by regulating the alternative splicing ofGLS to
preferentially induce the expression of GAC, the oncogenic iso-
form of GLS (Redis et al. 2016). This is further supported by our
data that both the G and T alleles can spontaneously initiate stable
MDS/MPN phenotype inmice. Although the rs6983267 “G” allele
has been touted to be the cancer-predisposing allele, our data illus-
trate that both alleles are functional and, in fact, equally essential
and independently sufficient for MDS/MPN. The microarray data
demonstrated that both alleles function via independent path-
ways to induce oncogenesis. However, when present concurrently
(in rs6983267-RE+ cases), it initiates a global dysregulation of
immune-associated genes as well as their specific targets. Although
the BM microenvironment and the inherent heterogeneity of
the BM composition might also play an important role in the dys-
regulation of immune system, our data indicate that it can, at least
partially, be attributed to CCAT2 overexpression. According to our
data, while the constitutive overexpression of CCAT2-G and
CCAT2-T independently induce EZH2 repression, the concurrent
presence of both alleles further augments the repression of
EZH2. Thus, we argue that although the CCAT2 transcript is the
“active” functional entity, the specific alleles contribute to its
oncogenicity by independently regulating common and distinct
pathways, affording it to have multiple far-reaching targets.
Additionally, because rs6983267-RE also existed in CCAT2 mice,
we propose the presence of a positive feedback loop, wherein
CCAT2 transcript could act in cis to regulate the occurrence of
rs6983267-RE at its locus, while rs6983267-RE could control the
allelic distribution of CCAT2 transcripts.
For years, scientists endorsed the central dogma of biology,
which holds that the RNA transcripts used as templates for protein
assembly are a perfect match to the original DNA. However, with
the advent of the Human Genome Project and the discovery
of noncoding RNAs, this simplistic concept has been repeatedly
challenged. DNA–RNA discrepancies have been previously report-
ed: peripheral blood mononuclear cells (Ju et al. 2011), immortal-
ized B cells (Peng et al. 2012), at the interleukin-12 receptor β1 (IL-
12Rβ1) locus in peripheral blood mononuclear cells (Turner et al.
2015), and at three specific loci in the human mitochondrial
DNA from different cell types (Bar-Yaacov et al. 2013). Notably,
these DNA–RNA discrepancies have only been reported in normal
tissues and their incidence inhumandiseases is still unknown. The
primary difference between these DNA–RNA discrepancies and
rs6983267-RE is that to date, DNA–RNA discrepancies are identi-
fied exclusively in non-SNP regions of the human genome, where-
as we discovered rs6983267-RE in one of the well-characterized
SNP region in the human genome. Further studies are required
to understand whether SNP-specific RE exists at other actively
transcribed SNP loci and in other malignancies.
One question that arises from this study is the mechanism of
rs6983267-RE occurrence. Although the classical A-to-I RNA edit-
ing relies on chemical modification of the nucleotides, this cannot
be the case with rs6983267-RE because it involves variation
between a purine (G) and a pyrimidine (T) nucleotide. We believe
that “nucleotide switching” or “nucleotide insertion” mecha-
nisms are at play in the rs6983267-RE-positive cases; however, fur-
ther work is needed to elucidate the intricatemechanisms. Because
the RNA modifications introduced by rs6983267-RE are distinct
from the classic A-to-I RNA editing mechanism, we propose two
potential explanations for this specific RE occurrence. First, the
complexity of the SNP genomic locus might be the catalyst in
rs6983267-RE occurrence: The 8q24 region is one of themost com-
monly amplified regions in the human genome (Beroukhim et al.
2010), the rs6983267 SNP has been reported to predispose individ-
uals to several cancers (Haiman et al. 2007; Tomlinson et al. 2007;
Zanke et al. 2007), the gDNA itself forms a large molecular loop
and acts as an enhancer to Myc located about 500 kb upstream
(Pomerantz et al. 2009), and the oncogenic lncRNA CCAT2 tran-
scribed from this region also acts as an enhancer to Myc (Ling
et al. 2013). The instability of the genomic region might lead to
active alterations in the RNA transcription mechanism, resulting
in rs6983267-RE. Second, the widely described clonal heterogene-
ity ofMDS/MPNBMcellsmight cause a small population ofCD34+
BM cells to be genomically diverse at the SNP locus from the
majority of CD34+ BM cells. The signal generated by this small
subpopulation of cells will not be detected in gDNA using Sanger
sequencing and restriction digestions, resulting in rs6983267-RE.
One caveat is that these proposed explanations are based on the
observation of rs6983267-RE inMDS patients andmight not stand
true in mouse model, since the genomic complexity does not
occur in the mouse model.
In conclusion, this study elucidates the biological importance
of actively transcribed cancer-associated rs6983267 SNP and its
accompanying lncRNA CCAT2 in MDS/MPN, a disease not yet
associated with this SNP. The CCAT2 transgenic mice can serve
as a robust model to study stable de novo MDS/MPN that does
not progress to secondary AML and as a preclinical model for eval-
uating new therapies for premalignant MDS/MPN. Our mouse
model also provides a unique opportunity to further explore the
intricate mechanisms of transcriptional regulation by nonexonic
SNPs and lncRNAs. Finally, the presence of SNP-specific RE at
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the cancer-predisposing rs6983267 SNP located within the most
commonly amplified 8q24 region is indicative of an enigmatic
genomic puzzle that warrants further investigation.
Methods
Generation of CCAT2 transgenic mice
CCAT2 transgenic mice were generated using random integration
approach. A 1.7-kb human cDNA of CCAT2 expressing either the
G or T allele was cloned into a vector backbone containing the
CAG promoter, along with the eGFP reporter gene followed by
IRES site. Pronuclear injection of the entire 4.5-kb linearized insert
and generation of founder mice was performed by the MDACC
Genetically Engineered Mouse Facility. The founders were mated
withC57BL/6Nmice. Pupswere screened for presence of the trans-
gene by PCR and Southern blot analysis on tail-extracted DNA
according to standard protocols. For PCR screening, three different
primer pairs were used. Pups showing positive detection by both
PCR and Southern blot were identified as founders. All primers
and probes used for this study are given in Supplemental Table
S1A. All the protocols and experiments were conducted according
to the guidelines of theMDACC Institutional Animal Care andUse
Committee (IACUC).
Transplantation experiment
B6.SJL-Ptprca Pepcb/BoyJ mice (Jackson Laboratories) expressing
the CD45.1marker were used for the transplantation experiments.
BM cells were extracted from 9-mo-old CCAT2 (confirmed to have
MDS/MPN) or WT mice, crushed in cold 1× PBS with 2% FBS, and
passed through a 40 µm filter. B6.SJL-Ptprca Pepcb/BoyJmice 6–12
wk old were lethally irradiated (9.5 Gy) and injected with 1 × 106
BM cells from CCAT2 (CCAT2-to-WT group) or WT (WT-to-WT
group) mice. Irradiated recipients were maintained on sterile water
containing 0.5 g/L of enrofloxacin for 2 wk after irradiation. Blood
levels were monitored for 3 mo.
Clinical samples
CD34+ cells from BM of 86 myelodysplastic syndrome (MDS)
patients and eight healthy individuals were obtained from MD
Anderson Cancer Center tissue bank (MDACC cohort). A second
set of peripheral blood mononuclear cells from 54 MDS patients
and 55 healthy volunteer samples were obtained from University
of Medicine and Pharmacy Iuliu Hatieganu, Romania (ROM co-
hort). All samples were collected according to the institutional
policies and obtained following patient’s informed consent.
Tissue samples were obtained from fresh surgical specimens frozen
in liquid nitrogen and stored at −80°C. Samples were de-identified
prior to any analyses using standard procedures. Clinical informa-
tion of the patients used in this study is provided in Supplemental
Table S2.
Detection of rs6983267-RE
gDNA and RNA were extracted from CD34+ BM cells and PB
mononuclear cells using standard protocols as described above.
Reverse transcription was performed using random hexamers
with SuperScript III Reverse Transcriptase or MultiScribe Reverse
Transcriptase according to the manufacturer’s protocol (Thermo
Fischer Scientific). End-point PCR was performed on the gDNA
and cDNA from the patients with high fidelity Advantage HF
PCR 2 kit (Clontech) or high fidelity Taq Polymerase (Thermo
Fischer Scientific) according themanufacturer’s protocol to ampli-
fy the 500-bp region encompassing the SNP. For the reaction,
50 ng DNA template was used. Primer sequences are available in
Supplemental Table S1A. Products were run on 2% agarose gel
to verify the amplicon size and purified using QIAquick PCR puri-
fication kit (Qiagen). The purified PCR product was used for Sanger
sequencing and restriction digestion as described below. Only
samples identified to be rs6983267-RE+ by both Sanger sequencing
and restriction digestion were considered as rs6983267-RE+ for
this study.
Sanger sequencing
Purified PCR product (20 ng/µL) was submitted for Sanger se-
quencing to the MD Anderson Sequencing and Microarray Core
Facility. Each rs6983267-RE+ sample was sequenced twice, using
forward and reverse primers. The sequencing results from gDNA
and cDNA from each patient were matched individually and
analyzed using SeqMan Pro (DNASTAR). Only clean sequences
with no background peaks were used for rs6983267-RE analysis.
Restriction digestion
Purified PCR product (200 ng) was used for restriction digestion
using Tsp45I enzyme for 1 h. The products were then run on 2%
agarose gel to identify the allele present.
Gene expression profiling analyses
Total RNA was extracted from BM cells of WT, CCAT2-G, and
CCAT2-Tmice as described above. RNA quality was assessed using
RNA 6000 Nano assay (Bioanalyzer, Agilent). The labeling and the
hybridization of mRNAs were performed according to Affymetrix
standard protocols. Briefly, 5 µg of total RNA was reverse tran-
scribed with an oligo(dT) primer that has a T7 RNA polymerase
promoter at the 5′ end. Second-strand synthesis was followed by
cRNA production with incorporation of biotinylated ribonucleo-
tides using the BioArray High Yield RNA Transcript Labeling Kit
T3 from Enzo Life Sciences. The labeled cRNA was fragmented
and hybridized to Affymetrix GeneChip Mouse Genome 230 4.0
arrays. GeneSpring GX software v.13 (Agilent Technologies) was
used for probe set summarization and robust multiarray average
(RMA) normalization procedures. The differentially expressed
genes were selected to have a >1.5-fold change difference between
the compared groups (average value), a <10%FDRusing Benjamini
and Hochberg corrected moderated t-test and P < 0.05. Gene
lists were uploaded to Ingenuity Pathway Analysis (Qiagen) for
Enrichment Analysis. EZH2 target gene list was obtained from
the Molecular Signatures Database (http://software.broadinstitute.
org/gsea/msigdb). The significance of overlap between CCAT2-
regulated genes and EZH2 targets was performed using hypergeo-
metric probability distribution analysis.
EZH2 expression analysis
Western blot staining for EZH2, H3K27me3, Histone 3, Vinculin
and GAPDH, and immunohistochemistry for EZH2 were per-
formed onmouse tissues, cell lines, and stable clones as previously
described (Ling et al. 2013). The antibodies used for the analyses
are listed in Supplemental Table S1A. RNA pulldown and RNA im-
munoprecipitation experiments were performed on CCAT2-over-
expressing cell lines as previously described (Redis et al. 2016).
For EZH2 protein stability analysis, cellular protein degradation
was monitored after blockage of de novo protein synthesis via cy-
cloheximide treatment. For this purpose, HEK293 cells transfected
with CCAT2-G, CCAT2-T, or Empty vector (E) were treated with
50 µg/mL final concentration of cycloheximide. Cells were har-
vested after cycloheximide treatment at indicated time points
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followed by protein extraction, SDS-PAGE, andWestern blot anal-
ysis to visualize protein degradation of EZH2.
Statistical analysis
The statistical analyses were performed usingGraphPad Prism. The
Shapiro–Wilk test was applied to determinewhether data followed
a normal distribution. Accordingly, the t-test or the nonparametric
Mann-Whitney–Wilcoxon test was applied to assess the relation-
ship between CCAT2 expression levels and clinical parameters,
or the experimental variables. CCAT2 RNA levels were analyzed
as a log-transformed continuous variable or as a dichotomized var-
iable based on the median level of CCAT2 RNA, and the log-rank
test was used to evaluate differences. All data are presented as the
mean values ± the standard error of the mean or median value
with 95% confidence interval (as specified) from at least three
independent experiments. Two-sided t-tests were used to test the
relationships between themeans of data sets, and P-values indicate
the probability of themeans compared, being equal with ∗P < 0.05,
∗∗P < 0.01, ∗∗∗P < 0.001, and ∗∗∗∗P < 0.0001.
Additional information on hematological measurements,
peripheral blood morphology, peripheral blood and bone marrow
histology, in situ hybridization, genomic instability analysis, flow
cytometry and mass cytometry analysis, RNA extraction, reverse
transcription, and real-time qPCR performed on these mice are
presented in Supplemental Materials.
Data access
Microarray data from this study have been submitted to the NCBI
Gene Expression Omnibus (GEO; https://www.ncbi.nlm.nih.gov/
geo/) under accession numberGSE106581. The Sanger sequencing
data have been submitted to NCBI Trace Archive (https://trace.
ncbi.nlm.nih.gov/Traces/trace.cgi) under Trace Identifier (TI)
numbers 2344290315–2344290801.
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